Fixed-dose combination therapy for the prevention of cardiovascular disease
- PMID: 25267903
- PMCID: PMC4176631
- DOI: 10.1002/14651858.CD009868
Fixed-dose combination therapy for the prevention of cardiovascular disease
Update in
-
Fixed-dose combination therapy for the prevention of cardiovascular disease.Cochrane Database Syst Rev. 2014 Apr 16;4(4):CD009868. doi: 10.1002/14651858.CD009868.pub2. Cochrane Database Syst Rev. 2014. Update in: Cochrane Database Syst Rev. 2017 Mar 06;3:CD009868. doi: 10.1002/14651858.CD009868.pub3. PMID: 24737108 Free PMC article. Updated.
Abstract
This is the protocol for a review and there is no abstract. The objectives are as follows: To determine the effectiveness of fixed-dose combination therapy on optimising CVD risk factors and reducing CVD fatal and non-fatal events for both primary and secondary prevention of CVD. Details of CVD events and risk factors included are listed in the methods. We will also determine any adverse events associated with taking fixed-dose combination therapy. This will include studies conducted in both developed and developing regions of the world.
References
-
- ALLHAT-investigators Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA. 2002;288(23):2981–97. - PubMed
-
- Armitage JM, Bowman L, Clarke RJ, Wallendszus K, Bulbulia R, Rahimi K, et al. Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. JAMA. 2010;303(24):2486–94. - PubMed
-
- Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–78. - PubMed
LinkOut - more resources
Full Text Sources